History and the present state of hypolipidaemic therapy
Authors:
R. Bartas 1; J. Kolář 2
Authors‘ workplace:
Lékárna Aqua, Karviná
1; Veterinární a farmaceutická univerzita Brno, Farmaceutická fakulta, Ústav aplikované farmacie
2
Published in:
Čes. slov. Farm., 2008; 57, 208-214
Category:
Review Articles
Overview
History of hypolipidaemic therapy is closely connected with the development of the knowledge of atherosclerosis pathogenesis and lipid metabolism. Isolation of statins (and also their synthesis) and their subsequent implementation in practice were a decisive discovery that affected contemporary cardiology. Statins rank among the most widely utilized drugs and some of them belong to very commercially successful preparations. There are very few therapeutic groups the therapeutic contribution of which is documented so well. Several prospective drugs with different mechanisms of effect are being developed at present.
Keywords:
hypolipidaemics – atherosclerosis – ischemic heart disease – statins
Sources
1. Pater, C.: Curr. Control. Trials Cardiovasc. Med., 2001; 2, 24–37.
2. Steinberg, D.: J. Lipid Res., 2004; 45, 1583–1593.
3. Steinberg, D.: J. Lipid Res., 2006; 47, 1–14.
4. Steinberg, D.: J. Lipid Res., 2005; 46, 179–190.
5. Steinberg, D.: J. Lipid Res., 2005; 46, 2037–2051.
6. All Nobel Laureates in Medicine [on line]., [cit. 2008-05-15]. Dostupný z www: <http://nobelprize.org/nobel_ prizes/medicine/laureates/index.html>
7. Endo, A.: J. Lipid Res., 1992; 33, 1569–1582.
8. Bultas, J., Karetová, D.: Pace News, 2004; 3, 1–4.
9. Steinberg, D.: J. Lipid Res., 2006; 47, 1339–1351.
10. Hlinomaz, O., Groch, L.: Interv. Akut. Kardiol., 2003; 2, 123–136.
11. Pfizer ukončil vývoj léku na cholesterol. [on line]., [cit. 2008-04-15]. Dostupný z www:<http://www.medical-tribune.cz/aktualita/1942>
12. Sobolová, L.: Klin. Farmakol. Farm., 2005; 19, 22–26.
13. Češka, R. , Doležal, T.: Farmakoterapie 2006; 2, 183–188.
14. Štulc, T. Ezetimib: zklamání ze studie ENHANCE. Lékařské listy 2008; 10, 30–31.
15. --: Farmakoterapie 2007; 4, 367.
16. Pikto-Pietkiewicz, W., Wołkowska, K., Pasierski, T.: Pharmacological Reports 2005; 57 (Suppl.), 10–19.
17. Scharnagl, H. et al.: Atherosclerosis 2000; 153, 69–80.
18. Locker, P. K. et al.: Clinical Pharmacology & Therapeutics 1995; 57, 73–88.
19. Tardif, J. et al.: JAMA, 2007; 297, 1675–1682.
20. Bultas, J.: Farmakoterapie, 2006; 2, 151–153.
21. UPDATE 2-US FDA tells Takeda to stop some TAK-475 trials. [on line]., [cit. 2008-04-15]. Dostupný z www: <http://www.reuters.com/article/governmentFilingsNews/idUST17428120071029>
22. Češka, R.: Kap Kardiol., 2006; 8, 22–25.
23. Bultas, J.: Interní medicína pro praxi, 2006; 7/8, 314–322.
24. Berger, A., Jones J. H. P., Abumweis, S., S.: Lipids Health Dis., 2004; 3, 1–19.
Labels
Pharmacy Clinical pharmacologyArticle was published in
Czech and Slovak Pharmacy
2008 Issue 5
Most read in this issue
- History and the present state of hypolipidaemic therapy
- Effect of montelukast on the treatment of asthma bronchiale in pediatric patients with perennial allergic rhinitis
- Medicinal preparations in Prague pharmacies at the end of the 16th century
- Impact of demographic factors on consumption of pharmaceuticals in the Czech Republic